Resources

Selected
  • Systematic reviews (SYSVAC)
Type of publications
Regions
Diseases
Vaccine topics
Target population
Publication date
3100 results found
2026 ∙ Kling, K. Falman, A. Branke, L. Ramharter, M. Rothe, C. Schonfeld, C. Grunewald, T.
Vaccination against chikungunya - a systematic review on the immunogenicity, tolerability, and safety of the live-attenuated vaccine (LAV) Ixchiq and the virus like particle (VLP) vaccine Vimkunya
All age groups Chikungunya Efficacy/effectiveness Safety Administration
Methodological quality (AMSTAR 2):
High
2026 ∙ Landicho, J. Bravo, T. A. Wachinger, J. Silvestre, C. Barnighausen, K. Scott, K. Barnighausen, T. McMahon, S. A. Renosa, M. D. C.
Vaccine preferences and their role for vaccine confidence and uptake: a meta-ethnography
All age groups Acceptance
Methodological quality (AMSTAR 2):
Not applicable
2025 ∙ Tololiu, K. E. Kurnianto, A. A. Dulahu, W. Y. Kocsor, F. Csokasi, K.
A meta-analysis of digital interventions to reduce vaccination-related pain in children
Newborn Children Adolescents Acceptance
Methodological quality (AMSTAR 2):
Not applicable
2025 ∙ Dhayfule, D. Wu, Y. H. Ashyani, A. Li, M. C. Tsai, C. S. Chen, P. L. Nordling, T.
A meta-analysis of vaccine efficacy from phase III clinical trials of approved vaccines against SARS-CoV-2 and variants
All age groups COVID-19 Efficacy/effectiveness Administration
Methodological quality (AMSTAR 2):
Critically low
2025 ∙ Ndzouboukou, J. L. B. Kamara, A. A. Ullah, N. Lei, Q. Fan, X. L.
A Meta-Analysis on the Immunogenicity of Homologous versus Heterologous Immunization Regimens against SARS-CoV-2 Beta, Delta, and Omicron BA.1 VoCs in Healthy Adults
Adults Older adults COVID-19 Administration Efficacy/effectiveness
Methodological quality (AMSTAR 2):
Critically low
2025 ∙ Banga Ndzouboukou, J. L. Kamara, A. A. Ullah, N. Lei, Q. Fan, X. L.
A meta-analysis on the immunogenicity of prototype, monovalent-adapted and bivalent vaccines against SARS-CoV-2 wildtype, Omicron BA.1 and Omicron BA.4/5 in healthy adults
Adults Older adults COVID-19 Efficacy/effectiveness Administration
Methodological quality (AMSTAR 2):
Critically low
2025 ∙ Farina, S. Maio, A. Zaino, A. Russo, L. Ricciardi, W. Ieraci, R. Villani, L.
A review of childhood rotavirus vaccination policies and a presentation of vaccine coverage trends at national and regional level, Italy, 2016 to 2023
Europe Italy Newborn Children Rotavirus Coverage
Methodological quality (AMSTAR 2):
Not applicable
2025 ∙ Hamashima, Y. Breheny, K. Davies, S. R. Dawson, S. Thornton, Z. A. Aiton, E. Caldwell, D. M. Christensen, H. Higgins, J. P. T. Yates, J. Letley, L. French, C. E.
A synthesis of economic data from randomized trials of recipient-focused interventions to increase vaccine uptake
All age groups Economic aspects
Methodological quality (AMSTAR 2):
Not applicable
2025 ∙ Vittrup, D. M. Charabi, S. Jensen, A. Stensballe, L. G.
A systematic review and meta-analysis of adverse events following measles-containing vaccines in infants less than 12 months of age
Newborn Measles Safety Administration
Methodological quality (AMSTAR 2):
Critically low
2025 ∙ Kitano, T. Salmon, D. A. Dudley, M. Z. Saldanha, I. J. Thompson, D. A. Engineer, L.
A Systematic Review and Meta-Analysis of Health-State Utility Values for Infectious Diseases With Pandemic Potential and Associated Vaccine Adverse Reactions
All age groups Safety
Methodological quality (AMSTAR 2):
High
Loading...